US FDA Grants Accelerated Approval for New Multiple Myeloma Therapy

The U.S. Food and Drug Administration has granted accelerated approval to iberdomide (Zenbexus) in combination with other agents for adults with relapsed or refractory multiple myeloma. This marks the introduction of the first cereblon E3 ligase modulator (CELMoD) agent, providing a new class of treatment for patients who have undergone at least one prior therapy for this blood cancer.